Macrolide Antibiotic Purification via Ultrafiltration
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current chromatography-based purification methods for macrolide antibiotics, such as vancomycin, result in products with unsatisfactory white color and stability issues, failing to meet European Pharmacopoeia standards due to residual impurities.
Innovation Solution
The process involves ultrafiltration using membranes with specific retention values (lower than 30,000 Da) to separate macrolide antibiotics from impurities, followed by concentration via reverse osmosis and lyophilization to produce a stable white powder, optimizing membrane selection for each antibiotic.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If chromatography-based purification methods are used, then purity is improved, but color quality deteriorates (light pink to brownish)
Solution Approach 1:
The patent extracts and removes specific colored impurities from the macrolide antibiotic solution using ultrafiltration membranes with molecular weight cutoff of 3000 Da or lower. These membranes selectively retain impurities responsible for pink/brownish coloration while allowing the antibiotic to pass through, thereby separating the harmful colored components from the active substance without requiring chromatography.
Solution Approach 2:
The patent employs ultrafiltration membranes with specific porosity characteristics (molecular weight cutoff ≤3000 Da) to physically separate impurities from the macrolide antibiotic. The porous membrane structure enables size-based filtration where smaller antibiotic molecules pass through while larger colored impurities are retained, achieving both purification and color improvement simultaneously.
2Manufacturing precision
If chromatography-based purification methods are used, then purity is improved, but stability deteriorates (color changes over time)
Solution Approach 1:
The patent removes unstable colored impurities that cause deterioration over time by passing the antibiotic solution through ultrafiltration membranes. These membranes extract and retain impurities responsible for color instability, leaving behind a stable antibiotic product that maintains its white color characteristics during storage without the progressive browning seen in chromatography-purified products.
Solution Approach 2:
The patent changes the purification parameter from chromatographic separation to ultrafiltration based on molecular size exclusion. This parameter change fundamentally alters which impurities are removed, specifically eliminating those that cause color instability while preserving the antibiotic's stability profile, resulting in a product that meets European Pharmacopoeia stability requirements.
3Illumination intensity
If ultrafiltration with low retention membrane is used, then color quality is improved (white powder), but impurity removal efficiency may vary
Solution Approach 1:
The patent applies local quality by using ultrafiltration membranes with specifically optimized molecular weight cutoff (≤3000 Da) tailored to the size characteristics of macrolide antibiotics and their associated impurities. This localized optimization of membrane pore size ensures effective retention of colored impurities while maintaining high passage of the antibiotic, achieving both color quality and impurity removal efficiency simultaneously.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method effectively removes impurities, ensuring a white powder with reduced absorption at 450 nm, meeting European Pharmacopoeia standards and maintaining color stability over time.
Implementation Method 1
subjecting the solution to ultrafiltration with a membrane having nominal retention lower than 30,000 Da
Implementation Method 2
The purified solution is preferably concentrated by reversed osmosis
Implementation Method 3
lyophilized at the optimized conditions of pressure and temperature to obtain a white powder
Data Source
AI summary
The present invention concerns a process for the purification of macrolide antibiotics. More specifically it concerns a process for the purification of macrolide antibiotics that result in a white powder. The powder remains white also after some time of storage. The process of the present invention is performed by dissolving the macrolide antibiotics, e.g. commercial vancomycin hydrochloride, in water and subjecting the solution to ultrafiltration with a membrane having nominal retention lower than 30,000 Da, preferably of 10,000 Da. The purified solution is preferably concentrated by reversed osmosis and then lyophilized at the optimized conditions of pressure and temperature to obtain a white powder.